InsiderTradr

Cutia Therapeutics (2487.HK)

HKSE · HKD · Healthcare · Biotechnology

HK$0.745 (+8.76%) as of

Key statistics

Market cap
277.98M
Forward P/E
4.53
EPS (TTM)
-0.870
Dividend yield
0.00%
52-week range
0.600 – 8.190
Beta
0.78
Revenue (TTM)
332.58M
Profit margin
-84.55%
Analyst target
HK$7.73
Volume
17.40k

About Cutia Therapeutics

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People's Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication. The company provides CU-40102, a topical finasteride spray for androgenetic alopecia treatment; and CU-10201, a topical 4% minocycline foam for acne vulgaris treatment. It is also involved in the development of CU-20401, a recombinant mutant collagenase, currently under Phase II clinical trial for submental adipose accumulation (submental fat); CU-40101, a topical small molecule thyroid hormone receptor agonist liniment, currently completed Phase I clinical trial for the treatment of androgenetic alopecia; and CU-30101, a localized topical lidocaine and tetracaine compound topical anesthesia cream, completed Phase III clinical trial for surface dermatologic operations. In addition, the company provides CATAME, a technology platform that enables the development of a wide range of product dosage forms and the relevant formulation technology. Further, it offers product pipeline of creams, sprays, ointments, aerosol foams and other dosage forms through the CATAME platform. The company was incorporated in 2019 and is headquartered in Shanghai, China.

Sector
Healthcare
Industry
Biotechnology
Headquarters
Shanghai, China
Employees
268

cutiatx.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks